Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Mary Ann Anderson, Constantine Tam, Thomas E Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David CS Huang, John F Seymour, Andrew W Roberts
Blood | AMER SOC HEMATOLOGY | Published : 2017
Awarded by Australian National Health and Medical Research Council
Awarded by Leukemia and Lymphoma Society (SCOR)
The clinical trials were funded by AbbVie and Genentech. This research was also supported by scholarships, fellowships, and grants from the Australian National Health and Medical Research Council (Research Fellowships, Program Grants 1016647, 1016701, Independent Research Institutes Infrastructure Support Scheme grant 9000220) (A.W.R., D.C.S.H.), the Leukemia and Lymphoma Society (SCOR grants 7001-13), the Victorian Cancer Agency, the Cancer Council Victoria, the Australian Cancer Research Foundation, and a Victorian State Government Operational Infrastructure Support grant. Past support by a fellowship from the Webster bequest and current support by the Snowdome Foundation is acknowledged (M.A.A.).